Skip to main
AMGN
AMGN logo

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 67%
Sell 8%
Strong Sell 0%

Bulls say

Amgen has demonstrated robust financial performance with a 40% increase in sales in the third quarter of 2025 compared to the same quarter in 2024, alongside double-digit growth in 16 products. The company's revenue guidance for FY25 has been raised to a range of $35.8 billion to $36.6 billion, indicating strong momentum in its established franchises. Furthermore, Amgen is investing in its research and development with an anticipated growth rate of over 20% in 2025, suggesting a commitment to innovation and long-term growth.

Bears say

Amgen is projected to experience only ~1% total revenue growth in 2026 compared to 2025, amidst anticipated worldwide sales declines of ~28% for Prolia and ~39% for Xgeva. Despite possessing a robust pipeline with emerging products like MariTide and olpasiran, there is limited visibility into their ability to counteract the erosion of the base business and the impending loss of exclusivity for key franchises. This forecast, combined with muted R&D spending growth and the challenges posed by emerging therapies, contributes to a negative outlook on Amgen's stock.

Amgen (AMGN) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 67% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 12 analysts, Amgen (AMGN) has a Hold consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $316.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $316.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.